UroGen Pharma Ltd. (URGN) Free cash flow 2016–2025
UroGen Pharma Ltd. (URGN) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$162.7MFY2025 · since FY2016: $3.5M → -$162.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$162.7M | -67.7% |
| FY2024 | -$97.1M | -26.8% |
| FY2023 | -$76.6M | +12.8% |
| FY2022 | -$87.8M | -2.5% |
| FY2021 | -$85.6M | +20.0% |
| FY2020 | -$107.1M | -50.1% |
| FY2019 | -$71.3M | -88.3% |
| FY2018 | -$37.9M | -285.1% |
| FY2017 | -$9.8M | -381.6% |
| FY2016 | $3.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More URGN financial trends
URGN RevenueURGN Net incomeURGN Net marginURGN Gross profitURGN Gross marginURGN Operating incomeURGN Operating marginURGN Operating cash flowURGN Capital expendituresURGN Return on equityURGN Stock buybacksURGN Dividends paidURGN Total assetsURGN Total liabilitiesURGN Shareholders’ equityURGN overview →